Literature DB >> 22009420

Effect of hepatobiliary uptake of Gd-EOB-DTPA on the hepatic venous phase of dynamic magnetic resonance imaging on a 3.0-T apparatus: comparison between Gd-EOB-DTPA and Gd-DTPA.

Yasunari Fujinaga1, Ayumi Ohya, Tsuyoshi Matsushita, Masahiro Kurozumi, Kazuhiko Ueda, Yoshihiro Kitou, Hitoshi Ueda, Masumi Kadoya.   

Abstract

PURPOSE: We aimed to reveal the difference in contrast enhancement of the abdominal organs and major vessels on dynamic contrast-enhanced magnetic resonance imaging (DCM-MRI) using gadoxetic sodium (Gd-EOB-DTPA) and gadopentetate dimeglumine (Gd-DTPA) in the same patients.
MATERIALS AND METHODS: DCM-MRI using Gd-EOBDTPA and Gd-DTPA were performed in the same 17 patients. Precontrast and DCM-MRI images [arterial phase (AP), portal venous phase (PP), hepatic venous phase (HP)] were acquired before and after bolus injection of each contrast agent. The organ-to-muscle ratio [liver (L/M), spleen (S/M), aorta (A/M), portal vein (P/M), hepatic vein (V/M)] were calculated at each phase and analyzed statistically.
RESULTS: There was no significant difference between Gd-EOB-DTPA and Gd-DTPA images regarding the L/M or V/M mean on precontrast images or the mean of L/M at AP and L/M at the PP. At the AP, PP, and HP, the means of S/M, A/M, P/M, and V/M with Gd-EOBDTPA were lower than those with Gd-DTPA. On HP, The mean L/M with Gd-EOB-DTPA was higher than that with Gd-DTPA.
CONCLUSION: On 3-T DCM-MRI using Gd-EOB-DTPA, contrast enhancement of the organs, except for the liver, was lower than that on DCM-MRI using Gd-DTPA. The HP was already affected by hepatobiliary uptake in Gd-EOB-DTPA.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22009420     DOI: 10.1007/s11604-011-0615-5

Source DB:  PubMed          Journal:  Jpn J Radiol        ISSN: 1867-1071            Impact factor:   2.374


  21 in total

1.  Signal-to-noise ratio and signal-to-noise efficiency in SMASH imaging.

Authors:  D K Sodickson; M A Griswold; P M Jakob; R R Edelman; W J Manning
Journal:  Magn Reson Med       Date:  1999-05       Impact factor: 4.668

2.  Focal liver lesions: evaluation of the efficacy of gadobenate dimeglumine in MR imaging--a multicenter phase III clinical study.

Authors:  J Petersein; A Spinazzi; A Giovagnoni; P Soyer; F Terrier; R Lencioni; C Bartolozzi; L Grazioli; A Chiesa; R Manfredi; P Marano; E L Van Persijn Van Meerten; J L Bloem; C Petre; G Marchal; A Greco; M T McNamara; A Heuck; M Reiser; M Laniado; C Claussen; H E Daldrup; E Rummeny; M A Kirchin; G Pirovano; B Hamm
Journal:  Radiology       Date:  2000-06       Impact factor: 11.105

3.  Generalized autocalibrating partially parallel acquisitions (GRAPPA).

Authors:  Mark A Griswold; Peter M Jakob; Robin M Heidemann; Mathias Nittka; Vladimir Jellus; Jianmin Wang; Berthold Kiefer; Axel Haase
Journal:  Magn Reson Med       Date:  2002-06       Impact factor: 4.668

4.  A simple method for estimating the noise level in a signal region of an MR image.

Authors:  Michael C Steckner
Journal:  Med Phys       Date:  2010-09       Impact factor: 4.071

5.  Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths.

Authors:  Martin Rohrer; Hans Bauer; Jan Mintorovitch; Martin Requardt; Hanns-Joachim Weinmann
Journal:  Invest Radiol       Date:  2005-11       Impact factor: 6.016

6.  [Signal-to-noise ratio measurement in parallel MRI with subtraction mapping and consecutive methods].

Authors:  Hiroshi Imai; Tosiaki Miyati; Akio Ogura; Tsukasa Doi; Toshio Tsuchihashi; Yoshio Machida; Masato Kobayashi; Kouzou Shimizu; Yoshihiro Kitou
Journal:  Nihon Hoshasen Gijutsu Gakkai Zasshi       Date:  2008-08-20

7.  Qualitative and quantitative evaluation of hepatocellular carcinoma and cirrhotic liver enhancement using Gd-EOB-DTPA.

Authors:  Bernd B Frericks; Christoph Loddenkemper; Alexander Huppertz; Steffi Valdeig; Andrea Stroux; Marion Seja; Karl-Jürgen Wolf; Thomas Albrecht
Journal:  AJR Am J Roentgenol       Date:  2009-10       Impact factor: 3.959

8.  Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging.

Authors:  B Hamm; T Staks; A Mühler; M Bollow; M Taupitz; T Frenzel; K J Wolf; H J Weinmann; L Lange
Journal:  Radiology       Date:  1995-06       Impact factor: 11.105

9.  Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings.

Authors:  Alexander Huppertz; Thomas Balzer; Anthony Blakeborough; Josy Breuer; Andrea Giovagnoni; Gertraud Heinz-Peer; Michael Laniado; Riccardo M Manfredi; Didier G Mathieu; Dieter Mueller; Peter Reimer; Philip J Robinson; Michael Strotzer; Matthias Taupitz; Thomas J Vogl
Journal:  Radiology       Date:  2004-01       Impact factor: 11.105

10.  Diagnostic efficacy of gadoxetic acid (Primovist)-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesions.

Authors:  Renate Hammerstingl; Alexander Huppertz; Josy Breuer; Thomas Balzer; Anthony Blakeborough; Rick Carter; Lluis Castells Fusté; Gertraud Heinz-Peer; Werner Judmaier; Michael Laniado; Riccardo M Manfredi; Didier G Mathieu; Dieter Müller; Koenraad Mortelè; Peter Reimer; Maximilian F Reiser; Philip J Robinson; Kohkan Shamsi; Michael Strotzer; Matthias Taupitz; Bernd Tombach; Gianluca Valeri; Bernhard E van Beers; Thomas J Vogl
Journal:  Eur Radiol       Date:  2007-12-06       Impact factor: 5.315

View more
  2 in total

1.  OATP1B3 Expression in Hepatocellular Carcinoma Correlates with Intralesional Gd-EOB-DTPA Uptake and Signal Intensity on Gd-EOB-DTPA-Enhanced MRI.

Authors:  Xiaojiao Zhou; Liling Long; Zhiqing Mo; Yajuan Li
Journal:  Cancer Manag Res       Date:  2021-02-09       Impact factor: 3.989

2.  Comparison of gadoxetic acid and gadopentetate dimeglumine-enhanced MRI for HCC detection: prospective crossover study at 3 T.

Authors:  Cecilia Besa; Suguru Kakite; Nancy Cooper; Marcelo Facciuto; Bachir Taouli
Journal:  Acta Radiol Open       Date:  2015-01-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.